Communiqués Exicure, Inc.

Actions

XCUR

US30205M3097

Recherche biotechnologique et médicale

Temps Différé Nasdaq 17:15:18 10/09/2026			Varia. 5j.	Varia. 1 janv.
1,370 ^USD	-4,19%		+11,39%	-74,72%

14/08	Exicure, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
30/06	Exicure, Inc. annonce des changements au sein de son conseil d'administration et de ses comités, effectifs au 30 juin 2026	CI

Communiqués

03/08	Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance	AQ
30/06	Exicure Announces Board and Committee Changes	AQ
10/06	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
01/06	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
23/04	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ
02/04	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions	AQ
25/03	Exicure, Inc. Reports Full Year 2025 Financial Results	AQ
05/02	Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant	AQ
21/01	Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings	AQ
08/12	Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting	AQ
07/11	Exicure, Inc. Reports Third Quarter 2025 Financial Results	AQ
03/11	New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting	AQ
06/10/25	Exicure Highlights Recent Achievements and Near-term Strategic Priorities	AQ
11/08/25	Exicure, Inc. Reports Second Quarter 2025 Financial Results	AQ
08/08/25	Exicure, Inc. Reports Second Quarter 2025 Financial Results	BU
04/08/25	Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements	BU
01/08/25	Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant	BU
27/06/25	Exicure, Inc. Reports First Quarter 2025 Financial Results	BU
28/05/25	Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q	BU
05/05/25	Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant	BU
15/04/25	Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma	BU
12/04/25	Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)	BU
18/03/25	Exicure, Inc. Reports Full Year 2024 Financial Results	BU
13/03/25	Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia	BU
22/01/25	CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.	BU